Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Factors affecting visual outcomes in patients with diabetic macular edema treated with ranibizumab.

Channa R, Sophie R, Khwaja AA, Do DV, Hafiz G, Nguyen QD, Campochiaro PA; READ-2 Study Group.

Eye (Lond). 2014 Mar;28(3):269-78. doi: 10.1038/eye.2013.245. Epub 2013 Nov 22.

2.

Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment.

Do DV, Nguyen QD, Khwaja AA, Channa R, Sepah YJ, Sophie R, Hafiz G, Campochiaro PA; READ-2 Study Group.

JAMA Ophthalmol. 2013 Feb;131(2):139-45.

PMID:
23544200
3.

Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study.

Nguyen QD, Shah SM, Heier JS, Do DV, Lim J, Boyer D, Abraham P, Campochiaro PA; READ-2 Study Group.

Ophthalmology. 2009 Nov;116(11):2175-81.e1. doi: 10.1016/j.ophtha.2009.04.023. Epub 2009 Aug 22.

PMID:
19700194
4.

Early treatment of cystoid macular edema secondary to branch retinal vein occlusion with intravitreal triamcinolone acetonide.

Yepremyan M, Wertz FD, Tivnan T, Eversman L, Marx JL.

Ophthalmic Surg Lasers Imaging. 2005 Jan-Feb;36(1):30-6.

PMID:
15688969

Supplemental Content

Loading ...
Support Center